Navigation Links
Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
Date:7/1/2008

REHOVOT, Israel, July 1 /PRNewswire-FirstCall/ -- Applisonix LTD (TASE: APLS), a developer of innovative ultrasound based solutions for the aesthetic market, announced today that the test conducted using its hair removal prototype achieved, following an initial treatment, average hair reduction of 38%, which positions its efficacy within the top professional long-term hair removal solutions.

Applisonix' co-CEOs, Mr. Alon Goren and Mr. Uri Amir, stated that the test results indicate that the technology developed by Applisonix can be safely and effectively implemented for men and women. Mr. Goren estimates that compared to commercially available long-term hair removal solutions, Applisonix' solutions are planned to be safer, less painful, more affordable, and applicable to all hair and skin tones, Mr. Amir added that the company intends to launch its first device, Selectif(TM), in the first quarter of 2009, as planned.

Applisonix conducted tests on men and women for a period of several months. The test results were examined by Prof. Kassuto (Milan, Italy), an external, independent, internationally recognized expert. Prof. Kassuto verified and evaluated the findings and concluded that the new technology's efficacy is similar to the efficacy of the top commercial light based systems, and without any side effects, and regardless of hair and skin color.

In addition, it appears from Prof. Kassuto's review, that following the initial treatment using the prototype and Applisonix' technology (IMPRESA(TM)), there was an average 38% hair reduction, compared to the controlled area, which was not treated. The treatment was given to 36 people, men and women, with different hair colors and skin tones, and the results were statistically significant.

These results reflect the new technology's capability of competing with expensive professional light-based systems. From studies published in this field, it seems that with most light based systems, one
'/>"/>

SOURCE Applisonix Ltd.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Silence Therapeutics Announces Board Changes
2. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
7. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
8. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
9. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
10. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
11. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2009)...Newswire/ -- In two recent COPD studies sponsored ...pressors (Ultra and Ultra II) were used to show th... LP, Mylan Inc.) improves pulmonary function. , ...oducts as the exclusive nebulizer systems for rece...PD. Sutherland et al. used an open-label crossove...
(Date:6/29/2009)...ssess RSV Burden in Outpatient Setting During Firs...c Research , , GAITHERSBURG, Md., June 29 /PR...mmitment to pediatric research with today,s announ...y designed to assess the burden of respiratory syn...weeks gestational age (GA) in outpatient settings ...
(Date:6/28/2009)...RNewswire-FirstCall/ -- Sangamo BioSciences, Inc. ...rch milestone has been achieved in its Research an...-owned member of the Roche Group, for the generati...armaceutical protein production purposes using San... nuclease (ZFN) technology. Genentech scientists d...
(Date:6/26/2009)...endia,s Breast Cancer Recurrence Test MammaPrint,...sus Recommendations" issued,on 23 Jun 2009 12:00 ...dvised,that the subheadline was missing from the .... Complete, corrected release follows: , ...r Recurrence Test MammaPrint Included in,Internat...
Breaking Medicine Technology:PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies 2MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3/C O R R E C T I O N -- Agendia B.V./ 2/C O R R E C T I O N -- Agendia B.V./ 3Nasal Surgery Helps Ease Sleep Apnea Symptoms 17445 1Nasal Surgery Helps Ease Sleep Apnea Symptoms 17445 2Phone counseling improves quality of life immune systems of cervical cancer survivors 17441 1Phone counseling improves quality of life immune systems of cervical cancer survivors 17441 2Ground breaking new insight into the development of Alzheimers disease 17437 1Ground breaking new insight into the development of Alzheimers disease 17437 2LIFE FOR A CHILD Diabetes Documentary Accepted Into Competition at New Yorks Prestigious Tribeca Film Festival 17435 1LIFE FOR A CHILD Diabetes Documentary Accepted Into Competition at New Yorks Prestigious Tribeca Film Festival 17435 2LIFE FOR A CHILD Diabetes Documentary Accepted Into Competition at New Yorks Prestigious Tribeca Film Festival 17435 3LIFE FOR A CHILD Diabetes Documentary Accepted Into Competition at New Yorks Prestigious Tribeca Film Festival 17435 4LIFE FOR A CHILD Diabetes Documentary Accepted Into Competition at New Yorks Prestigious Tribeca Film Festival 17435 5LIFE FOR A CHILD Diabetes Documentary Accepted Into Competition at New Yorks Prestigious Tribeca Film Festival 17435 6
...RVING, Texas--(BUSINESS WIRE)--Jul 11, 2007 - The ...gy has published the early,results of a clinical s...gues, which concluded that the topical gel, Regene...ion in the pain and,itching of a rash that results...nhibitors. This ongoing supportive care trial is,l...
... Professor Jean-Francois Rossi Medical Hematolog...,C-reactive protein (CRP) is an acute-phase protei...temic inflammation. CRP measurement can complement...n and direct treatment. However, as economic rati...lth care sector, it is apparent that such areas of...
Other Medicine Technology:Clinical Study Shows Regenecare Relieves Pain and Itching of Skin,Rashes Caused by Widely Used Cancer Drugs 2Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 2Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 3Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 4
(Date:7/4/2009)...nt pain and injury, doctors say , , SATU...s are not as young as they used to be, exercise is...s are in order to stay injury-free. , "As bo... themselves from injuries when exercising," Dr. Ra...rthopaedic Surgeons, said in a news release. "A li...
(Date:7/3/2009)...gnise service excellence during National Customer ... London (PRWeb UK) July 3, 2009 -- Companies ...d to celebrate the importance of excellent custome...ice Week - 5-11 October., , ,Employers in all sect...and local authority see the week, which is organis...
(Date:7/3/2009)... in middle age may triple the risk, study shows ,...iddle-aged adults who live alone are twice as like...r in life compared to those who are married or liv...er among those who are divorced or widowed, accord...ers. , The study included 2,000 men and women i...
(Date:7/3/2009).../ -- Sundia MediTech, a leading,integrated pharma...n Shanghai,China announced today that Dr. Chen C...hemistry Services. , Prior to joining Sundi...ug,discovery and development company in San Diego...ior Director of Medicinal Chemistry of Neurocrine....
Breaking Medicine News(10 mins):Health News:Exercise Tips to Keep Boomers on Their Feet 2Health News:Businesses Urged to Sign Up and Celebrate Customer Service 2Health News:Living Alone Increases Odds of Developing Dementia 2Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2
...s at loggerheads with the pharmaceutical industry ... generic medicines. // While Thailand argues it wi...to its citizens, drug companies maintain that the ...and discourages foreign investment. "We were disa...
...e awareness about the ill effects of obesity in ch.../ The game is named as "Body Mechanics," and teach...laying the game. The game begins with an introduc...uro, a Yoda-like wise man. He requests players to ...
...approved by the UAE Ministry of Health (MOH) again...warded with a //prequalification status by the Wor... a vaccine against rotavirus gastroenteritis has r...fication endorses the Rotarix quality, safety and ...
...egulator said it has adopted a positive opinion re...on for Focetria, from Novartis //AG (NVS) Vaccines...demic influenza vaccine, intended for the preventi...eclared pandemic situation, once the pandemic vira...
Other Medicine News:Health News:Drug Companies Hit Out at Thai Generic Drug Scheme 2Health News:WHO Awards Prequalification Status to the First UAE Approved Vaccine 2
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Cross action serrated handle with polished finish.
Narrow smooth jaws. Serrated handle with polished finish.
Oval solid 24 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 20 mm. Serrated handle with locking thumb screw and polished finish.
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish.
Medicine Products: